Cargando…
HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression
BACKGROUND: Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor that carries a 5-y survival rate of 5%. Attempts at eliciting a clinically relevant anti-GBM immune response in brain tumor patients have met with limited success, which is due to brain immune privilege, tumor immun...
Autores principales: | Curtin, James F, Liu, Naiyou, Candolfi, Marianela, Xiong, Weidong, Assi, Hikmat, Yagiz, Kader, Edwards, Matthew R, Michelsen, Kathrin S, Kroeger, Kurt M, Liu, Chunyan, Muhammad, A. K. M. Ghulam, Clark, Mary C, Arditi, Moshe, Comin-Anduix, Begonya, Ribas, Antoni, Lowenstein, Pedro R, Castro, Maria G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621261/ https://www.ncbi.nlm.nih.gov/pubmed/19143470 http://dx.doi.org/10.1371/journal.pmed.1000010 |
Ejemplares similares
-
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
por: Homet Moreno, Blanca, et al.
Publicado: (2015) -
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
por: Lassen, Amanda, et al.
Publicado: (2014) -
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
por: von Euw, Erika, et al.
Publicado: (2009) -
Human Flt3L Generates Dendritic Cells from Canine Peripheral Blood Precursors: Implications for a Dog Glioma Clinical Trial
por: Xiong, Weidong, et al.
Publicado: (2010) -
A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication
por: Zhou, Jing, et al.
Publicado: (2018)